Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors

We recently published These 10 Stocks are Winning Big. Esperion Therapeutics, Inc. (NASDAQ:ESPR) is one of the best-performing stocks on Monday.

Esperion Therapeutics extended its winning streak to a fifth consecutive day on Monday, adding 5.3 percent to close at $1.59 apiece as investors gobbled up shares ahead of its earnings release amid reports that it was set to be acquired by a Japan-based pharmaceutical company.

According to a post by @rumourbuyouts on X, pharmaceutical firm Otsuka is said to be in talks to fully acquire Esperion Therapeutics, Inc. (NASDAQ:ESPR) in a deal that could potentially be valued $900 million. The post added that the two companies are set to meet in August to discuss a deal.

Based on the social media handle, @rumourbuyouts is currently based in Japan and only has 177 followers.

Meanwhile, Esperion Therapeutics, Inc. (NASDAQ:ESPR) said that it is scheduled to release the results of its second quarter earnings performance before market open on August 5, Tuesday.

While we acknowledge the potential of ESPR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.